Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...

In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Shares of Biogen Inc. BIIB advanced 2.06% to $118.89 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.51% to 5,287.76 and ...

RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP) for people with ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

In the U.S., key risk factors for Alzheimer's disease were tied to cognitive function as early as ages 24 to 44. (Lancet ...

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.